Carregant...
Update on PARP Inhibitors in Breast Cancer
The single agent activity of PARP inhibitors (PARPi) in germline BRCA mutated (gBRCAm) breast and ovarian cancer suggests untapped potential for this new class of drug in breast cancer. The US Food and Drug Administration has approved three PARPi (olaparib, rucaparib, and niraparib) so far to treat...
Guardat en:
| Publicat a: | Curr Treat Options Oncol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7430202/ https://ncbi.nlm.nih.gov/pubmed/29644491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-018-0540-2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|